Skip to main content
Helmholtz Munich | Andreas Pfohl

Fr1da Study

The Fr1da study, the world's largest population-based screening for type 1 diabetes in children, was launched at Helmholtz Munich in 2015.

 

The Fr1da offers islet autoantibody screening to children aged 2 to 10 years, living in Bavaria, Germany, with the aim to diagnose type 1 diabetes at a presymptomatic stage to

  • prevent life-threatening diabetic ketoacidosis (DKA)
  • minimize psychological burden and uncertainty by education and care of those affected
  • help to set new standards for early diagnosis of type 1 diabetes
  • identify children who benefit from immune-based therapies to prevent insulin dependence

Children with a family history of type 1 diabetes (first- or second-degree relative) can participate in screening between the ages of 1 and 21 years. All children can participate twice within the respective age ranges.

The Fr1da study, the world's largest population-based screening for type 1 diabetes in children, was launched at Helmholtz Munich.

 

The Fr1da offers islet autoantibody screening to children aged 2 to 10 years, living in Bavaria, Germany, with the aim to diagnose type 1 diabetes at a presymptomatic stage to

  • prevent life-threatening diabetic ketoacidosis (DKA)
  • minimize psychological burden and uncertainty by education and care of those affected
  • help to set new standards for early diagnosis of type 1 diabetes
  • identify children who benefit from immune-based therapies to prevent insulin dependence

Children with a family history of type 1 diabetes (first- or second-degree relative) can participate in screening between the ages of 1 and 21 years. All children can participate twice within the respective age ranges.

 

Fr1da Science Newsletter

We will keep you updated on the most important developments of Fr1da projects and research.

If you are interested in receiving the Fr1da Science newsletter in the future, please subscribe.

Fr1da & SARS-CoV-2 Dashboard

Since January 2020, the Fr1da study additionally offers screening of antibodies to SARS-CoV-2.

By September 2022, the Fr1da study team has now tested up to 58,257 blood samples of our study participants for antibodies against SARS-CoV-2.

The study results are available in a dashboard along with an overview of the geographic distribution of antibody abundance. The figures are updated monthly.

Contact

Dr. rer. biol. hum. Christiane Winkler

Lead Scientist Research Area: Early Diagnosis & Staging of Type 1 Diabetes, and Phenotyping

Heidemannstraße 1, 80939 München